Latest Breaking News On - Top line clinical - Page 1 : comparemela.com

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor. | May 26, 2022

United statesAngelos stergiouMichaela fawcettJeffreys weberAllison sossRaquel conaLangone healthCompany wilmsGenfleet therapeutics shanghai incMerck co incStrategic communicationsLife sciences group incYork universityMelanoma research program centerPerlmutter cancer centerMemorial sloan kettering cancer center

SELLAS Life Sciences (SLS) Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda

SELLAS Life Sciences (SLS) Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAngelos stergiouJeffreys weberContactraquel cona michaela fawcettLangone healthPerlmutter cancer center at new york universityCompany wilmsGenfleet therapeutics shanghai incMerck co incLife sciences group incMelanoma research program centerMemorial sloan kettering cancer centerWall streetSciences groupClinical trial collaborationSupply agreement